Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Darin Lippoldt. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Darin Lippoldt har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:NBIX / Neurocrine Biosciences, Inc. | Chief Legal Officer | 43 405 |
US:VOLC / Volcano Corp | EVP, General Counsel | 4 795 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Darin Lippoldt. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Darin Lippoldt som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-02-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 086 | 43 405 | −2,44 | 116,75 | −126 790 | 5 067 512 |
2025-02-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 2 017 | 44 491 | 4,75 | ||||
2025-02-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 098 | 42 474 | −2,52 | 116,76 | −128 202 | 4 959 264 |
2025-02-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 2 083 | 43 572 | 5,02 | ||||
2025-02-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
G - Gift | −190 | 41 489 | −0,46 | ||||
2025-02-12 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −911 | 41 679 | −2,14 | 118,25 | −107 727 | 4 928 600 |
2025-02-12 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 727 | 42 590 | 4,23 | ||||
2025-02-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 250 | 40 863 | −2,97 | 152,91 | −191 133 | 6 248 214 |
2025-02-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 2 373 | 42 113 | 5,97 | ||||
2024-08-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −2 996 | 39 740 | −7,01 | 154,01 | −461 423 | 6 120 477 |
2024-08-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 2 996 | 42 736 | 7,54 | 79,02 | 236 744 | 3 376 999 | |
2024-07-18 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −7 004 | 39 740 | −14,98 | 150,00 | −1 050 590 | 5 960 944 |
2024-07-18 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 7 004 | 46 744 | 17,62 | 79,02 | 553 456 | 3 693 711 | |
2024-02-15 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 098 | 39 740 | −2,69 | 132,99 | −146 028 | 5 285 217 |
2024-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −911 | 38 755 | −2,30 | 134,24 | −122 289 | 5 202 312 |
2024-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 041 | 37 939 | −2,67 | 142,17 | −147 995 | 5 393 647 |
2024-02-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 250 | 37 005 | −3,27 | 140,65 | −175 810 | 5 204 672 |
2024-01-24 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −10 000 | 35 882 | −21,80 | 139,86 | −1 398 553 | 5 018 288 |
2024-01-24 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 10 000 | 45 882 | 27,87 | 79,02 | 790 200 | 3 625 596 | |
2023-12-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −20 830 | 35 882 | −36,73 | 119,86 | −2 496 648 | 4 300 756 |
2023-12-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 20 830 | 56 712 | 58,05 | 43,24 | 900 689 | 2 452 227 | |
2023-11-29 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −10 919 | 35 882 | −23,33 | 112,27 | −1 225 911 | 4 028 587 |
2023-09-01 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
G - Gift | −190 | 46 801 | −0,40 | ||||
2023-08-23 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −2 132 | 46 991 | −4,34 | 107,39 | −228 951 | 5 046 270 |
2023-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −911 | 44 973 | −1,99 | 104,08 | −94 815 | 4 680 695 |
2023-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −12 801 | 44 157 | −22,47 | 102,42 | −1 311 067 | 4 522 520 |
2023-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 522 | 32 660 | −4,45 | 102,24 | −155 613 | 3 339 247 |
2023-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 041 | 31 290 | −3,22 | 105,80 | −110 141 | 3 310 592 |
2023-02-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 250 | 30 357 | −3,95 | 109,97 | −137 464 | 3 338 396 |
2022-11-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −5 082 | 29 234 | −14,81 | 125,04 | −635 442 | 3 655 352 |
2022-11-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 5 082 | 34 316 | 17,38 | 43,24 | 219 746 | 1 483 824 | |
2022-11-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −4 518 | 29 234 | −13,39 | 125,02 | −564 851 | 3 654 905 |
2022-11-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 4 518 | 33 752 | 15,45 | 43,24 | 195 358 | 1 459 436 | |
2022-11-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −400 | 29 234 | −1,35 | 125,00 | −50 000 | 3 654 250 |
2022-11-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 400 | 29 634 | 1,37 | 43,24 | 17 296 | 1 281 374 | |
2022-11-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −10 000 | 29 234 | −25,49 | 120,09 | −1 200 899 | 3 510 708 |
2022-11-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 10 000 | 39 234 | 34,21 | 43,24 | 432 400 | 1 696 478 | |
2022-10-28 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −4 923 | 29 234 | −14,41 | 115,04 | −566 332 | 3 363 018 |
2022-10-28 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 4 923 | 34 157 | 16,84 | 43,24 | 212 871 | 1 476 949 | |
2022-10-28 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −5 077 | 29 234 | −14,80 | 115,02 | −583 966 | 3 362 547 |
2022-10-28 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 5 077 | 34 311 | 17,37 | 43,24 | 219 529 | 1 483 608 | |
2022-10-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −10 000 | 29 234 | −25,49 | 111,04 | −1 110 446 | 3 246 278 |
2022-10-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 10 000 | 39 234 | 34,21 | 43,24 | 432 400 | 1 696 478 | |
2022-09-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
G - Gift | −100 | 29 234 | −0,34 | ||||
2022-09-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
G - Gift | −100 | 29 334 | −0,34 | ||||
2022-03-22 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −8 455 | 29 396 | −22,34 | 95,05 | −803 656 | 2 794 119 |
2022-03-22 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −300 | 37 851 | −0,79 | 95,00 | −28 500 | 3 595 845 |
2022-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −911 | 38 112 | −2,33 | 79,51 | −72 435 | 3 030 323 |
2022-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 041 | 37 296 | −2,72 | 80,74 | −84 048 | 3 011 212 |
2022-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 522 | 36 363 | −4,02 | 80,78 | −122 947 | 2 937 410 |
2022-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −605 | 34 993 | −1,70 | 80,54 | −48 729 | 2 818 490 |
2022-02-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 9 492 | 9 492 | |||||
2022-02-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 64 638 | 64 638 | |||||
2021-12-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
G - Gift | −120 | 34 448 | −0,35 | ||||
2021-03-29 |
|
4/A | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 45 546 | 45 546 | |||||
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −36 194 | 0 | −100,00 | 35,99 | −1 302 622 | ||
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −6 008 | 34 361 | −14,88 | 116,21 | −698 160 | 3 992 923 |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 6 008 | 40 369 | 17,48 | 35,99 | 216 228 | 1 452 880 | |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −186 | 34 361 | −0,54 | 117,55 | −21 864 | 4 039 136 |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 186 | 34 547 | 0,54 | 35,99 | 6 694 | 1 243 347 | |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −30 000 | 34 361 | −46,61 | 116,16 | −3 484 806 | 3 991 381 |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 30 000 | 64 361 | 87,31 | 35,99 | 1 079 700 | 2 316 352 | |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 6 908 | 6 908 | |||||
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 41 444 | 41 444 | |||||
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 522 | 34 361 | −4,24 | 116,72 | −177 650 | 4 010 654 |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 198 | 32 991 | −3,50 | 116,74 | −139 859 | 3 851 488 |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −687 | 31 914 | −2,11 | 116,69 | −80 166 | 3 724 038 |
2021-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −605 | 30 627 | −1,94 | 114,05 | −69 003 | 3 493 129 |
2020-11-16 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −2 257 | 30 082 | −6,98 | 90,72 | −204 755 | 2 729 033 |
2020-08-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | −2 257 | 28 051 | −7,45 | 118,87 | −268 297 | 3 334 518 | |
2020-07-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −1 657 | 36 194 | −4,38 | 35,99 | −59 635 | 1 302 622 | |
2020-07-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 657 | 26 021 | −5,99 | 136,02 | −225 386 | 3 539 387 |
2020-07-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 657 | 27 678 | 6,37 | 35,99 | 59 635 | 996 131 | |
2020-06-25 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Incentive Stock Option |
M - Exercise | −5 000 | 0 | −100,00 | 32,99 | −164 950 | ||
2020-06-25 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −5 000 | 26 021 | −16,12 | 130,00 | −650 000 | 3 382 730 |
2020-06-25 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 5 000 | 31 021 | 19,22 | 32,99 | 164 950 | 1 023 383 | |
2020-05-20 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Incentive Stock Option |
M - Exercise | −5 000 | 5 000 | −50,00 | 32,99 | −164 950 | 164 950 | |
2020-05-20 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −5 000 | 26 021 | −16,12 | 120,00 | −600 000 | 3 122 520 |
2020-05-20 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 5 000 | 31 021 | 19,22 | 32,99 | 164 950 | 1 023 383 | |
2020-04-28 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 934 | 26 021 | −6,92 | 99,49 | −192 416 | 2 588 861 |
2020-02-11 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 522 | 24 124 | −5,93 | 103,32 | −157 247 | 2 492 398 |
2020-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 7 897 | 7 897 | |||||
2020-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 49 844 | 49 844 | |||||
2020-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 198 | 22 755 | −5,00 | 101,47 | −121 556 | 2 308 847 |
2020-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −605 | 21 678 | −2,72 | 103,15 | −62 407 | 2 236 114 |
2020-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 145 | 21 133 | −5,14 | 102,88 | −117 800 | 2 174 216 |
2019-11-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Incentive Stock Option |
M - Exercise | −3 375 | 10 000 | −25,23 | 32,99 | −111 341 | 329 900 | |
2019-11-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −6 625 | 0 | −100,00 | 32,99 | −218 559 | ||
2019-11-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −3 375 | 20 103 | −14,38 | 110,02 | −371 307 | 2 211 672 |
2019-11-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 3 375 | 23 478 | 16,79 | 32,99 | 111 341 | 774 539 | |
2019-11-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −6 625 | 20 103 | −24,79 | 110,00 | −728 750 | 2 211 330 |
2019-11-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 6 625 | 26 728 | 32,96 | 32,99 | 218 559 | 881 757 | |
2019-09-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −6 736 | 6 625 | −50,42 | 32,99 | −222 221 | 218 559 | |
2019-09-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −6 736 | 20 103 | −25,10 | 100,00 | −673 600 | 2 010 300 |
2019-09-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 6 736 | 26 839 | 33,51 | 32,99 | 222 221 | 885 419 | |
2019-08-27 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −1 600 | 13 361 | −10,69 | 32,99 | −52 784 | 440 779 | |
2019-08-27 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 600 | 19 961 | −7,42 | 100,00 | −160 000 | 1 996 100 |
2019-08-27 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 600 | 21 561 | 8,02 | 32,99 | 52 784 | 711 297 | |
2019-08-27 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −1 664 | 14 961 | −10,01 | 32,99 | −54 895 | 493 563 | |
2019-08-27 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 664 | 19 961 | −7,69 | 100,09 | −166 555 | 1 997 958 |
2019-08-27 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 664 | 21 625 | 8,34 | 32,99 | 54 895 | 713 409 | |
2019-07-31 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −15 831 | 0 | −100,00 | 18,15 | −287 333 | ||
2019-07-31 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −15 831 | 19 961 | −44,23 | 92,13 | −1 458 569 | 1 839 081 |
2019-07-31 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 15 831 | 35 792 | 79,31 | 18,15 | 287 333 | 649 625 | |
2019-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 11 567 | 11 567 | |||||
2019-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 62 506 | 62 506 | |||||
2019-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −791 | 19 646 | −3,87 | 83,52 | −66 063 | 1 640 810 |
2019-02-06 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −470 | 18 162 | −2,52 | 88,11 | −41 409 | 1 600 168 |
2019-02-06 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −755 | 17 482 | −4,14 | 88,08 | −66 501 | 1 539 830 |
2018-03-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −1 979 | 15 831 | −11,11 | 18,15 | −35 919 | 287 333 | |
2018-03-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 979 | 16 062 | −10,97 | 88,47 | −175 090 | 1 421 066 |
2018-03-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 979 | 18 041 | 12,32 | 18,15 | 35 919 | 327 444 | |
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
F - Taxes | −787 | 16 062 | −4,67 | 82,48 | −64 912 | 1 324 794 | |
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 12 250 | 12 250 | |||||
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 4 600 | 4 600 | |||||
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 26 050 | 26 050 | |||||
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −1 979 | 17 810 | −10,00 | 18,15 | −35 919 | 323 252 | |
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | −758 | 14 574 | −4,94 | 83,13 | −63 012 | 1 211 529 | |
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 979 | 13 157 | −13,07 | 83,11 | −164 482 | 1 093 528 |
2018-02-07 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 979 | 15 136 | 15,04 | 18,15 | 35 919 | 274 718 | |
2018-01-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −1 979 | 19 789 | −9,09 | 18,15 | −35 919 | 359 170 | |
2018-01-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −1 979 | 13 157 | −13,07 | 79,36 | −157 053 | 1 044 140 |
2018-01-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 1 979 | 15 136 | 15,04 | 18,15 | 35 919 | 274 718 | |
2018-01-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −15 237 | 21 768 | −41,18 | 18,15 | −276 552 | 395 089 | |
2018-01-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −15 237 | 13 157 | −53,66 | 75,00 | −1 142 775 | 986 775 |
2018-01-02 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 15 237 | 28 394 | 115,81 | 18,15 | 276 552 | 515 351 | |
2017-12-11 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −2 955 | 37 005 | −7,39 | 18,15 | −53 633 | 671 641 | |
2017-12-11 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −2 955 | 13 157 | −18,34 | 75,00 | −221 625 | 986 775 |
2017-12-11 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 2 955 | 16 112 | 22,46 | 18,15 | 53 633 | 292 433 | |
2017-12-06 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −6 279 | 39 960 | −13,58 | 18,15 | −113 964 | 725 274 | |
2017-12-06 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −6 279 | 13 157 | −32,31 | 75,04 | −471 160 | 987 267 |
2017-12-06 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 6 279 | 19 436 | 47,72 | 18,15 | 113 964 | 352 763 | |
2017-11-17 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-qualified Stock Option |
M - Exercise | −9 900 | 22 492 | −30,56 | 18,15 | −179 685 | 408 230 | |
2017-11-17 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −9 900 | 13 157 | −42,94 | 73,05 | −723 191 | 961 114 |
2017-11-17 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 9 900 | 23 057 | 75,25 | 18,15 | 179 685 | 418 485 | |
2017-09-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −100 | 56 139 | −0,18 | 18,15 | −1 815 | 1 018 923 | |
2017-09-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −100 | 13 157 | −0,75 | 60,00 | −6 000 | 789 420 |
2017-09-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 100 | 13 257 | 0,76 | 18,15 | 1 815 | 240 615 | |
2017-08-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −5 000 | 56 239 | −8,16 | 18,15 | −90 750 | 1 020 738 | |
2017-08-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −5 000 | 13 157 | −27,54 | 55,00 | −275 000 | 723 635 |
2017-08-14 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 5 000 | 18 157 | 38,00 | 18,15 | 90 750 | 329 550 | |
2017-05-23 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Non-Qualified Stock Option |
M - Exercise | −10 000 | 61 239 | −14,04 | 18,15 | −181 500 | 1 111 488 | |
2017-05-23 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −10 000 | 13 157 | −43,18 | 53,27 | −532 700 | 700 873 |
2017-05-23 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 10 000 | 23 157 | 76,01 | 18,15 | 181 500 | 420 300 | |
2017-04-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −204 | 13 157 | −1,53 | 51,23 | −10 451 | 674 033 |
2017-04-13 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −12 861 | 13 361 | −49,05 | 50,41 | −648 323 | 673 528 |
2017-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −132 | 1 222 | −9,75 | 44,62 | −5 890 | 54 526 |
2017-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Option |
A - Award | 9 100 | 9 100 | |||||
2017-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 68 400 | 68 400 | |||||
2017-02-08 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −821 | 0 | −100,00 | 43,13 | −35 410 | |
2016-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 20 500 | 20 500 | |||||
2016-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 41 200 | 41 200 | |||||
2016-02-09 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 8 700 | 8 700 | |||||
2015-11-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
M - Exercise | −23 761 | 71 239 | −25,01 | 18,15 | −431 262 | 1 292 988 | |
2015-11-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
S - Sale | X | −23 761 | 0 | −100,00 | 52,92 | −1 257 432 | |
2015-11-10 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
M - Exercise | 23 761 | 23 761 | 18,15 | 431 262 | 431 262 | ||
2015-02-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 30 000 | 30 000 | 32,99 | 989 700 | 989 700 | ||
2015-02-05 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Restricted Stock Unit |
A - Award | 25 000 | 25 000 | |||||
2014-11-04 |
|
4 | NBIX |
NEUROCRINE BIOSCIENCES INC
Stock Option |
A - Award | 95 000 | 95 000 | |||||
2014-11-04 | 3 | NBIX |
NEUROCRINE BIOSCIENCES INC
Common Stock |
0 | ||||||||
2014-03-20 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −1 377 | 4 795 | −22,31 | 23,03 | −31 711 | 110 424 |
2014-03-03 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −535 | 6 172 | −7,98 | 21,72 | −11 620 | 134 056 |
2014-03-03 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −1 201 | 2 401 | −33,34 | ||||
2014-03-03 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 1 201 | 6 304 | 23,54 | ||||
2014-02-21 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −504 | 5 103 | −8,99 | 21,86 | −11 017 | 111 552 |
2014-02-21 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −1 132 | 3 395 | −25,01 | ||||
2014-02-21 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 1 132 | 5 607 | 25,30 | ||||
2014-02-19 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −310 | 4 475 | −6,48 | 21,36 | −6 622 | 95 586 |
2014-02-19 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −700 | 700 | −50,00 | ||||
2014-02-19 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 700 | 4 785 | 17,14 | ||||
2014-02-19 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −307 | 4 085 | −6,99 | 21,36 | −6 558 | 87 256 |
2014-02-14 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
A - Award | 7 483 | 7 483 | |||||
2014-02-14 |
|
4 | VOLC |
Volcano Corp
Performance Shares |
M - Exercise | −694 | 1 387 | −33,35 | ||||
2014-02-14 |
|
4 | VOLC |
Volcano Corp
Performance Shares |
A - Award | 2 081 | 2 081 | |||||
2014-02-14 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 694 | 4 392 | 18,77 | ||||
2014-01-17 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −750 | 3 698 | −16,86 | 21,15 | −15 862 | 78 213 |
2014-01-03 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −289 | 4 448 | −6,10 | 21,68 | −6 266 | 96 433 |
2014-01-03 |
|
4 | VOLC |
Volcano Corp
Performance Shares |
M - Exercise | −760 | 760 | −50,00 | ||||
2014-01-03 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 760 | 4 737 | 19,11 | ||||
2013-04-16 |
|
4/A | VOLC |
Volcano Corp
Restricted Stock Units |
A - Award | 4 527 | 4 527 | |||||
2013-04-16 |
|
4/A | VOLC |
Volcano Corp
Non-Qualified Stock Option (Right to Buy) |
A - Award | 7 522 | 7 522 | |||||
2013-04-16 |
|
4/A | VOLC |
Volcano Corp
Non-Qualified Stock Option (Right to Buy) |
A - Award | 19 885 | 19 885 | |||||
2013-03-01 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −1 201 | 3 602 | −25,01 | ||||
2013-03-01 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −516 | 3 227 | −13,79 | 21,68 | −11 189 | 69 977 |
2013-03-01 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 1 201 | 3 743 | 47,25 | ||||
2013-02-22 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −345 | 2 542 | −11,95 | 24,67 | −8 512 | 62 715 |
2013-02-22 |
|
4/A | VOLC |
Volcano Corp
Restricted Stock Units |
A - Award | 7 519 | 7 519 | |||||
2013-02-21 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
A - Award | 7 343 | 7 343 | |||||
2013-02-21 |
|
4 | VOLC |
Volcano Corp
Non-Qualified Stock Option (Right to Buy) |
A - Award | 12 493 | 12 493 | |||||
2013-02-21 |
|
4 | VOLC |
Volcano Corp
Performance Shares |
M - Exercise | −760 | 1 520 | −33,33 | ||||
2013-02-21 |
|
4 | VOLC |
Volcano Corp
Performance Shares |
A - Award | 2 280 | 2 280 | |||||
2013-02-21 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 760 | 2 887 | 35,73 | ||||
2013-02-19 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −313 | 2 127 | −12,83 | 25,23 | −7 897 | 53 666 |
2013-02-19 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −700 | 1 400 | −33,33 | ||||
2013-02-19 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 700 | 2 440 | 40,23 | ||||
2012-03-29 |
|
4/A | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −296 | 1 740 | −14,54 | 28,07 | −8 309 | 48 842 |
2012-03-29 |
|
4/A | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −700 | 2 100 | −25,00 | ||||
2012-03-29 |
|
4/A | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 700 | 2 036 | 52,40 | ||||
2012-02-29 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
A - Award | 4 803 | 4 803 | |||||
2012-02-29 |
|
4 | VOLC |
Volcano Corp
Employee Stock Option (Right to Buy) |
A - Award | 6 527 | 6 527 | |||||
2012-02-17 |
|
4 | VOLC |
Volcano Corp
Common Stock |
S - Sale | X | −296 | 404 | −42,29 | 28,07 | −8 309 | 11 340 |
2012-02-17 |
|
4 | VOLC |
Volcano Corp
Common Stock |
M - Exercise | 700 | 700 | |||||
2012-02-17 |
|
4 | VOLC |
Volcano Corp
Restricted Stock Units |
M - Exercise | −700 | 2 100 | −25,00 |